IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its ...

This collaboration broadens access to advanced monitoring solutions for uveal melanoma patients in the United States, helping to address the needs of a largely underserved patient population. By ...

Producing the highest accuracy, the 9-gene set produced became the basis of the final classifier. When applied to multiple ...

For patients with metastatic uveal melanoma, what are the treatment options? Marlana M. Orloff, M.D.: Metastatic uveal melanoma is unique in that when patients recur, close to 90% or more recur in ...

Marlana M. Orloff, M.D.: Hello, and welcome to CURE®'s Educated Patient Sound Bites on metastatic uveal melanoma. I’m Dr. Marlana Orloff, an associate professor of medicine at Thomas Jefferson ...

MADRID — The positive effect of the bispecific fusion protein tebentafusp on the overall survival of patients with uveal melanoma in the IMCgp100-202 study lasted through at least 36 months of ...

Researchers have identified a new drug combination that is effective against metastatic uveal melanoma cells in preclinical studies. Uveal melanoma is a very aggressive type of melanoma that affects ...

Chicago — For patients with uveal melanoma, the most common eye cancer in adults, survival outcomes have improved in recent years, after treatment modalities shifted from systemic to liver-directed ...

Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...